The management of drug drug interactions is in particular of importance when elderly multimorbide patients are in need of multiple drug therapy. Many drug interactions are dose dependent and can be optimized by appropriate dosing. The cases of rosuvastatin/leflunomide or rosuvastatin/ leflunomide/ticagrelor combo therapy are presented in the Journal "Gerontology and Geriatric Medicine" demonstrating how AI supported interaction checking may reconcile multiple pharmacokinetic effects of the MDDI type and potentially serious adverse drug interaction including the increased Adverse Drug Risk (ADR) of acute kidney injury (AKI) or acute renal failure (ARF). Click here to read the full article.
